

# The World Health Organization's global strategy for pre drug resistance

Antiviral Therapy  
13 Suppl 2, 1-13

Citation Report

#	ARTICLE	IF	CITATIONS
1	Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37°C and high humidity. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 33-36.	1.3	38
2	The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. <i>Bioinformatics</i> , 2009, 25, 1197-1198.	1.8	159
3	Transmitted drug resistance in nonsubtype B HIV-1 infection. <i>HIV Therapy</i> , 2009, 3, 447-465.	0.6	31
4	Antiretroviral Drug Resistance Surveillance among Treatment-Naïve Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3156-3158.	1.4	20
5	TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. <i>Journal of Virological Methods</i> , 2009, 159, 185-193.	1.0	35
6	Antiretroviral Therapy as HIV Prevention: Status and Prospects. <i>American Journal of Public Health</i> , 2010, 100, 1867-1876.	1.5	76
7	Population-Based Monitoring of HIV Drug Resistance in Namibia With Early Warning Indicators. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 27-31.	0.9	39
8	Re-thinking global health sector efforts for HIV and tuberculosis epidemic control: promoting integration of programme activities within a strengthened health system. <i>BMC Public Health</i> , 2010, 10, 394.	1.2	14
9	Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. <i>BMC Public Health</i> , 2010, 10, 430.	1.2	30
10	Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). <i>HIV Medicine</i> , 2010, 11, 519-529.	1.0	25
11	Predictors of Virologic Failure in HIV-1-Infected Adults Receiving First-Line Antiretroviral Therapy in 8 Provinces in China. <i>Clinical Infectious Diseases</i> , 2010, 50, 264-271.	2.9	74
12	Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 298-304.	1.5	155
13	How HIV treatment could result in effective prevention. <i>Future Virology</i> , 2010, 5, 405-415.	0.9	8
14	Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 5-12.	0.5	114
15	HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-Naïve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High. <i>PLoS ONE</i> , 2011, 6, e23091.	1.1	43
16	What do mathematical models tell us about the emergence and spread of drug-resistant HIV?. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 131-140.	1.5	16
17	Point-of-care nucleic acid testing for infectious diseases. <i>Trends in Biotechnology</i> , 2011, 29, 240-250.	4.9	688
18	High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. <i>Journal of the International AIDS Society</i> , 2011, 14, 30.	1.2	45

#	ARTICLE	IF	CITATIONS
19	The Global Status of HIV Drug Resistance: Clinical and Public-Health Approaches for Detection, Treatment and Prevention. <i>Infectious Disorders - Drug Targets</i> , 2011, 11, 124-133.	0.4	18
20	Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis. <i>Current HIV Research</i> , 2011, 9, 355-366.	0.2	6
21	Atazanavir Concentration in Hair Is the Strongest Predictor of Outcomes on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2011, 52, 1267-1275.	2.9	116
22	Drug Resistance Surveillance in Resource-Poor Settings: Current Methods and Considerations for TB, HIV, and Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 192-199.	0.6	20
23	Monitoring of Early Warning Indicators for HIV Drug Resistance in Antiretroviral Therapy Clinics in Zimbabwe. <i>Clinical Infectious Diseases</i> , 2012, 54, S313-S316.	2.9	16
24	A Retrospective Survey of HIV Drug Resistance Among Patients 1 Year After Initiation of Antiretroviral Therapy at 4 Clinics in Malawi. <i>Clinical Infectious Diseases</i> , 2012, 54, S355-S361.	2.9	15
25	HIV-1 Drug Resistance Resulting from Antiretroviral Therapy Far Exceeds That From Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2012, 55, 303-304.	2.9	27
26	Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistanceâ€”HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. <i>International Journal of Epidemiology</i> , 2012, 41, 43-54.	0.9	53
27	Multidrug Resistance Among New Tuberculosis Cases. <i>Epidemiology</i> , 2012, 23, 293-300.	1.2	13
28	Evaluation of In-house Genotyping Assay Performance Using Dried Blood Spot Specimens in the Global World Health Organization Laboratory Network. <i>Clinical Infectious Diseases</i> , 2012, 54, S273-S279.	2.9	28
29	Surveillance of Transmitted Drug-Resistant HIV Among Young Pregnant Women in Ouagadougou, Burkina Faso. <i>Clinical Infectious Diseases</i> , 2012, 54, S317-S319.	2.9	8
30	The HIV-1 Epidemic: Low- to Middle-Income Countries. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007187-a007187.	2.9	89
31	HIV Drug Resistance Early Warning Indicators in Cohorts of Individuals Starting Antiretroviral Therapy Between 2004 and 2009: World Health Organization Global Report From 50 Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, S280-S289.	2.9	62
32	Sequence Quality Analysis Tool for HIV Type 1 Protease and Reverse Transcriptase. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 894-901.	0.5	30
33	Primary Drug Resistance in South Africa: Data from 10 Years of Surveys. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 558-565.	0.5	51
34	Transmitted Drug Resistance Among Antiretroviral-Naive Patients with Established HIV Type 1 Infection in Santo Domingo, Dominican Republic and Review of the Latin American and Caribbean Literature. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 667-674.	0.5	20
35	Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011. <i>Clinical Infectious Diseases</i> , 2012, 54, S245-S249.	2.9	48
36	Surveillance of Transmitted HIV-1 Drug Resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005â€”2009. <i>Clinical Infectious Diseases</i> , 2012, 54, S334-S338.	2.9	36

#	ARTICLE	IF	CITATIONS
37	Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. <i>Lancet, The</i> , 2012, 380, 1250-1258.	6.3	324
38	Genotyping External Quality Assurance in the World Health Organization HIV Drug Resistance Laboratory Network During 2007–2010. <i>Clinical Infectious Diseases</i> , 2012, 54, S266-S272.	2.9	22
39	Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. <i>BMC Infectious Diseases</i> , 2012, 12, 382.	1.3	30
40	The Origin and Evolutionary History of HIV-1 Subtype C in Senegal. <i>PLoS ONE</i> , 2012, 7, e33579.	1.1	20
41	Early Warning Indicators for HIV Drug Resistance in Cameroon during the Year 2010. <i>PLoS ONE</i> , 2012, 7, e36777.	1.1	18
42	Molecular and Phylogeographic Analysis of Human Immuno-deficiency Virus Type 1 Strains Infecting Treatment-naive Patients from Kigali, Rwanda. <i>PLoS ONE</i> , 2012, 7, e42557.	1.1	8
43	HIV-1 Genetic Diversity and Transmitted Drug Resistance Mutations among Patients from the North, Central and South Regions of Angola. <i>PLoS ONE</i> , 2012, 7, e42996.	1.1	24
44	Virological failure rates and HIV drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. <i>Journal of the International AIDS Society</i> , 2012, 15, 17985.	1.2	52
45	Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008–2010: lessons and challenges for low-resource settings. <i>BMC Public Health</i> , 2013, 13, 308.	1.2	22
46	Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2013, 207, S49-S56.	1.9	117
47	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. <i>Infection, Genetics and Evolution</i> , 2013, 18, 125-131.	1.0	58
48	Pharmacy and Self-Report Adherence Measures to Predict Virological Outcomes for Patients on Free Antiretroviral Therapy in Tamil Nadu, India. <i>AIDS and Behavior</i> , 2013, 17, 2253-2259.	1.4	17
49	Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. <i>Bulletin of the World Health Organization</i> , 2013, 91, 377-385E.	1.5	115
50	Field Evaluation of a Broadly Sensitive HIV-1 In-House Genotyping Assay for Use with both Plasma and Dried Blood Spot Specimens in a Resource-Limited Country. <i>Journal of Clinical Microbiology</i> , 2013, 51, 529-539.	1.8	26
51	Comparison of Ahlstrom Grade 226, Munktell TFN, and Whatman 903 Filter Papers for Dried Blood Spot Specimen Collection and Subsequent HIV-1 Load and Drug Resistance Genotyping Analysis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 55-60.	1.8	20
52	Capacity building and predictors of success for HIV drug resistance testing in the Asia-Pacific region and Africa. <i>Journal of the International AIDS Society</i> , 2013, 16, 18580.	1.2	9
53	Increasing trends in primary NNRTI resistance among newly HIV-diagnosed individuals in Buenos Aires, Argentina. <i>Journal of the International AIDS Society</i> , 2013, 16, 18519.	1.2	8
54	Personal barriers to antiretroviral therapy adherence: Case studies from a rural Uganda prospective clinical cohort. <i>African Health Sciences</i> , 2013, 13, 311-9.	0.3	8

#	ARTICLE	IF	CITATIONS
55	Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda. PLoS ONE, 2013, 8, e64345.	1.1	31
56	HIV Drug Resistance Early Warning Indicators in Namibia for Public Health Action. PLoS ONE, 2013, 8, e65653.	1.1	6
57	Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients. PLoS ONE, 2013, 8, e62057.	1.1	17
58	HIV Drug Resistance Early Warning Indicators in Namibia with Updated World Health Organization Guidance. PLoS ONE, 2014, 9, e100539.	1.1	17
59	Development, Validation and Clinical Evaluation of a Low Cost In-House HIV-1 Drug Resistance Genotyping Assay for Indian Patients. PLoS ONE, 2014, 9, e105790.	1.1	8
60	The Prevalence of HIV-1 Drug Resistance among Antiretroviral Treatment Na <sup>+</sup> ve Individuals in Mainland China: A Meta-Analysis. PLoS ONE, 2014, 9, e110652.	1.1	13
61	Field Study of Dried Blood Spot Specimens for HIV-1 Drug Resistance Genotyping. Journal of Clinical Microbiology, 2014, 52, 2868-2875.	1.8	28
62	Impact of Human Immunodeficiency Virus Type-1 Sequence Diversity on Antiretroviral Therapy Outcomes. Viruses, 2014, 6, 3855-3872.	1.5	10
63	Performance and Logistical Challenges of Alternative HIV-1 Virological Monitoring Options in a Clinical Setting of Harare, Zimbabwe. BioMed Research International, 2014, 2014, 1-10.	0.9	5
64	Genetic Analysis and Natural Polymorphisms in HIV-1 gp41 Isolates from Maputo City, Mozambique. AIDS Research and Human Retroviruses, 2014, 30, 603-609.	0.5	4
65	Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infectious Diseases, 2014, 14, 181.	1.3	34
66	Monitoring prevention or emergence of HIV drug resistance: results of a population-based foundational survey of early warning indicators in mainland Tanzania. BMC Infectious Diseases, 2014, 14, 196.	1.3	11
67	Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 3585-3598.	1.4	105
68	Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C. Journal of Virological Methods, 2014, 210, 36-39.	1.0	11
69	Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India. Global Health Action, 2014, 7, 24861.	0.7	24
70	Antiretroviral therapy adherence strategies used by patients of a large HIV clinic in Lesotho. Journal of Health, Population and Nutrition, 2015, 33, 10.	0.7	16
71	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, e49-e56.	0.9	21
73	HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Na <sup>+</sup> ve individuals in Surabaya, Indonesia. AIDS Research and Therapy, 2015, 12, 5.	0.7	23

#	ARTICLE	IF	CITATIONS
74	Use of Amplification Refractory Mutation System PCR Assay as a Simple and Effective Tool To Detect HIV-1 Drug Resistance Mutations. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1662-1671.	1.8	15
75	Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 463-471.	0.9	14
76	Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 86-92.	0.6	28
77	The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. <i>Archives of Virology</i> , 2015, 160, 2051-2061.	0.9	10
78	HIV Drug Resistance Testing by High-Multiplex "Wide" Sequencing on the MiSeq Instrument. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6824-6833.	1.4	50
79	Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 941-947.	1.3	16
80	First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. <i>Journal of the International AIDS Society</i> , 2016, 19, 20773.	1.2	17
81	Prevalence of HIV Antiretroviral Drug Resistance and Its Impacts on HIV-1 Virological Failures in Jiangsu, China: A Cross-Sectional Study. <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	16
82	Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010. <i>BMC Research Notes</i> , 2016, 9, 302.	0.6	21
83	Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia. <i>Scientific Reports</i> , 2016, 6, 36000.	1.6	23
84	Antiretroviral resistance testing in people living with HIV. <i>The Cochrane Library</i> , 2017, , .	1.5	0
85	In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment. <i>Cell Reports</i> , 2017, 21, 600-611.	2.9	189
86	Decreasing prevalence of transmitted drug resistance among ART-naïve HIV-1-infected patients in Iceland, 1996-2012. <i>Infection Ecology and Epidemiology</i> , 2017, 7, 1328964.	0.5	6
87	Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa. <i>Infectious Diseases: Research and Treatment</i> , 2017, 10, 117863371774959.	0.7	9
88	Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure. <i>PLoS ONE</i> , 2017, 12, e0172960.	1.1	17
89	Predictors of first-line antiretroviral therapy failure amongst HIV-infected adult clients at Woldia Hospital, Northeast Ethiopia. <i>PLoS ONE</i> , 2017, 12, e0187694.	1.1	30
90	Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naïve individuals. <i>Journal of the International AIDS Society</i> , 2018, 21, e25032.	1.2	28
91	Comparison of antiretroviral drug resistance among treatment-naïve and treated HIV-infected individuals in Shiraz, Iran. <i>Archives of Virology</i> , 2018, 163, 99-104.	0.9	3

#	ARTICLE	IF	CITATIONS
92	Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PLoS ONE, 2018, 13, e0200505.	1.1	21
93	Virological failure among adolescents on ART, Harare City, 2017- a case-control study. BMC Infectious Diseases, 2018, 18, 469.	1.3	46
94	Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania. BMC Pharmacology & Toxicology, 2018, 19, 66.	1.0	1
95	HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013. PLoS ONE, 2018, 13, e0205446.	1.1	22
96	Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens. Open Forum Infectious Diseases, 2019, 6, ofz034.	0.4	1
97	Prevalence of HIV-1 transmitted drug resistance and viral suppression among recently diagnosed adults in São Paulo, Brazil. Archives of Virology, 2019, 164, 699-706.	0.9	10
98	Point-of-care viral load testing among adolescents and youth living with HIV in Haiti: a protocol for a randomised trial to evaluate implementation and effect. BMJ Open, 2020, 10, e036147.	0.8	3
99	HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China. Scientific Reports, 2020, 10, 7571.	1.6	7
100	HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study. AIDS Research and Therapy, 2020, 17, 6.	0.7	5
101	HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study. BMC Infectious Diseases, 2020, 20, 4.	1.3	53
102	Relationships between Viral Load, Neuroimaging and Neuropsychological Performance in Persons Living with HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 985-992.	0.9	4
103	Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland. Medical Science Monitor, 2017, 23, 682-694.	0.5	1
104	HIV Drug Resistance Surveillance Using Pooled Pyrosequencing. PLoS ONE, 2010, 5, e9263.	1.1	29
105	Evaluation of Three Sampling Methods to Monitor Outcomes of Antiretroviral Treatment Programmes in Low- and Middle-Income Countries. PLoS ONE, 2010, 5, e13899.	1.1	13
106	National Prevalence and Trends of HIV Transmitted Drug Resistance in Mexico. PLoS ONE, 2011, 6, e27812.	1.1	28
107	Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings. PLoS ONE, 2011, 6, e28184.	1.1	98
108	Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003-2010. PLoS ONE, 2012, 7, e33484.	1.1	56
109	Evidence That HIV-1 CRF01_AE Is Associated with Low CD4+T Cell Count and CXCR4 Co-Receptor Usage in Recently Infected Young Men Who Have Sex with Men (MSM) in Shanghai, China. PLoS ONE, 2014, 9, e89462.	1.1	55



#	ARTICLE	IF	CITATIONS
110	Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance Mutations. <i>PLoS ONE</i> , 2015, 10, e0125699.	1.1	37
111	Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran. <i>PLoS ONE</i> , 2015, 10, e0126955.	1.1	21
112	Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda. <i>PLoS ONE</i> , 2015, 10, e0145536.	1.1	23
113	The association between asymptomatic and mild neurocognitive impairment and adherence to antiretroviral therapy among people living with human immunodeficiency virus. <i>Southern African Journal of HIV Medicine</i> , 2018, 19, 674.	0.3	9
114	HIV drug resistance among naïve HIV-infected patients in Iran. <i>Journal of Research in Medical Sciences</i> , 2019, 24, 31.	0.4	3
115	TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 368-80.	0.0	3
117	The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART. <i>AIDS Reviews</i> , 2009, 11, 59-70.	0.5	10
118	Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges. <i>AIDS Reviews</i> , 2013, 15, 221-9.	0.5	28
119	Monitoring HIV Drug Resistance: Early Warning Indicators to Assess Performance of Thailand's Antiretroviral Treatment Program. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2017, 100, 944-952.	0.4	2
120	HIV Drug Resistance among Pre-treatment Cases in Thailand: Four Rounds of Surveys during 2006-2013. , 2018, 11, 6-13.		0
121	Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute/Early/Primary HIV Infection: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 718763.	1.6	13
122	Effects of Framingham 10-Year Cardiovascular Risk Score and Viral Load on Brain Integrity in Persons With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 79-87.	0.9	4
123	Consistent condom utilization and associated factors among HIV positive clients attending ART clinic at Pawi general hospital, North West Ethiopia. <i>PLoS ONE</i> , 2021, 16, e0261581.	1.1	3